Last update Feb. 12, 2020
Very Low Risk
Fibrocystic breasts are benign changes in breast tissue that occur in more than half of women and consist of the appearance of cysts, nodules and multiple thickening in both breasts that change in size with the menstrual cycle.
They can cause pain and increased sensitivity to touch, especially in the upper outer quadrant of the breast.
They are due to a benign proliferation of the alveolar system of hormonal origin (Brkic 2018, MedlinePlus 2018).
There may be bloody or greenish-brown discharge from the nipple. A case of vomiting of blood has been reported in an infant whose mother had fibrocystic breasts (Aksoy 2013).
Ultrasound and puncture biopsy may be required for diagnosis, especially if there are nodules larger than 2 cm.
Anti-inflammatories such as ibuprofen or paracetamol and oral contraceptives used for treatment are compatible with breastfeeding. No other treatment or dietary restriction is effective (Rohan 2008).
Symptomatology may appear during breastfeeding, but is not influenced by it (Bernardi 2012). Fibrocystic breasts do not contraindicate breastfeeding (Lawrence 2016 p610).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM